Alcobra Ltd. (NASDAQ:ADHD) – Equities research analysts at Roth Capital reduced their FY2016 earnings estimates for Alcobra in a research note issued on Wednesday. Roth Capital analyst M. Higgins now expects that the firm will earn ($0.84) per share for the year, down from their previous estimate of ($0.78). Roth Capital currently has a “Buy” rating and a $8.00 price target on the stock. Roth Capital also issued estimates for Alcobra’s Q4 2016 earnings at ($0.16) EPS, Q1 2017 earnings at ($0.15) EPS, Q2 2017 earnings at ($0.17) EPS, Q3 2017 earnings at ($0.17) EPS, Q4 2017 earnings at ($0.18) EPS, FY2017 earnings at ($0.66) EPS, FY2018 earnings at ($0.59) EPS, FY2019 earnings at $0.33 EPS and FY2020 earnings at $0.52 EPS.

ADHD has been the topic of several other reports. Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Tuesday, November 1st. Oppenheimer Holdings Inc. downgraded Alcobra from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 29th. Cantor Fitzgerald downgraded Alcobra from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research report on Thursday, September 29th. WBB Securities downgraded Alcobra from a “hold” rating to a “sell” rating and lowered their price objective for the company from $5.00 to $4.00 in a research report on Monday, September 12th. Finally, Piper Jaffray Cos. downgraded Alcobra from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $10.00 to $3.00 in a research report on Thursday, September 29th. One analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $5.14.

Earnings History and Estimates for Alcobra (NASDAQ:ADHD)

Alcobra (NASDAQ:ADHD) traded down 7.465% during trading on Friday, reaching $2.008. 145,960 shares of the company’s stock traded hands. Alcobra has a 12 month low of $1.77 and a 12 month high of $6.80. The company’s market capitalization is $55.34 million. The firm’s 50 day moving average is $2.23 and its 200-day moving average is $4.02.

Alcobra (NASDAQ:ADHD) last released its earnings results on Tuesday, November 15th. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.02. The business had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $4.30 million.

A number of large investors have recently modified their holdings of ADHD. BlackRock Fund Advisors boosted its stake in shares of Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock valued at $1,621,000 after buying an additional 6,516 shares during the last quarter. Jefferies Group LLC bought a new stake in shares of Alcobra during the second quarter valued at $533,000. VHCP Management II LLC boosted its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock valued at $6,530,000 after buying an additional 323,902 shares during the last quarter. VHCP Management LLC boosted its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares during the last quarter. Finally, Palo Alto Investors LLC boosted its stake in shares of Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the last quarter. 73.72% of the stock is currently owned by institutional investors.

About Alcobra

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

5 Day Chart for NASDAQ:ADHD

Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.